---
schema_version: "secwatch.filing_event.v1"
accession: "0001601485-25-000096"
form_type: "8-K"
ticker: "ELTX"
cik: "0001601485"
company_name: "Elicio Therapeutics, Inc."
filed_at: "2025-06-04T23:59:59+00:00"
generated_at: "2026-05-19T23:55:23.596182+00:00"
event_type: "debt"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Elicio Therapeutics secures $10M senior secured note from board-affiliated investor

## Summary
- Issued $10M promissory note to GKCC (controlled by board member); interest rate up to 12.5%.
- Warrant to purchase 103,225 shares at $7.75 issued; immediately exercisable, 5-year term.
- Proceeds plus current cash expected to fund operations into Q1 2026.
- AMPLIFY-7P Phase 2 interim analysis for ELI-002 in PDAC anticipated in Q3 2025.
- Note matures June 3, 2028; 24-month interest-only period with lump-sum interest payment.

## SEC filing metadata
- accession: 0001601485-25-000096
- form_type: 8-K
- ticker: ELTX
- cik: 0001601485
- company_name: Elicio Therapeutics, Inc.
- filed_at: 2025-06-04T23:59:59+00:00
- event_type: debt
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 2.03, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1601485/000160148525000096/0001601485-25-000096-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1601485/000160148525000096/angn-20250604.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001601485-25-000096
- JSON: https://secwatch.observer/filing/0001601485-25-000096.json
- Plain text: https://secwatch.observer/filing/0001601485-25-000096.txt

## Key facts
- Debt Financings
  Elicio Therapeutics, Inc. incurred senior notes of $10.0 million with GKCC, LLC at Prime Rate plus 5.00%, maximum 12.5% per annum maturing June 3, 2028.
  - Instrument: senior notes
  - Principal: $10.0 million
  - Counterparty: GKCC, LLC
  - Rate: Prime Rate plus 5.00%, maximum 12.5% per annum
  - Maturity: June 3, 2028
  - Event: incurrence
  source text: On June 3, 2025, Elicio Therapeutics, Inc. (the “Company”) entered into a note purchase agreement (the “Note Purchase Agreement”) pursuant to which the Company issued a Senior Secured Promissory Note due June 3, 2028 (the “Promissory Note”) in the principal amount of $10.0 million (the “Note Financing”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1601485/000160148525000096/0001601485-25-000096-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.